依鲁替尼+ BR的安全性与已知的BR和依鲁替尼一致。

Safety of br + ibr was consistent with the known profiles for br and ibr.

youdao

依鲁替尼——首创药物，每天口服一次，布鲁顿酪氨酸激酶（BTK）的共价抑制剂——口服给药之后可快速从浆细胞内清除。

Ibrutinib (ibr), a first-in-class, once-daily, oral, covalent inhibitor of Bruton's tyrosine kinase (BTK), is rapidly eliminated from plasma after oral administration (Advani, JCO 2013).

youdao